nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—CYP1A2—Carmustine—lymphatic system cancer	0.265	0.428	CbGbCtD
Moclobemide—CYP2C19—Teniposide—lymphatic system cancer	0.193	0.312	CbGbCtD
Moclobemide—CYP2C9—Teniposide—lymphatic system cancer	0.161	0.259	CbGbCtD
Moclobemide—Oligomenorrhoea—Mechlorethamine—lymphatic system cancer	0.0541	0.142	CcSEcCtD
Moclobemide—Taste altered—Mitoxantrone—lymphatic system cancer	0.0142	0.0373	CcSEcCtD
Moclobemide—Sleep disorder—Fludarabine—lymphatic system cancer	0.00455	0.0119	CcSEcCtD
Moclobemide—Aggression—Bleomycin—lymphatic system cancer	0.00452	0.0119	CcSEcCtD
Moclobemide—Visual disturbance—Fludarabine—lymphatic system cancer	0.00415	0.0109	CcSEcCtD
Moclobemide—Tinnitus—Mechlorethamine—lymphatic system cancer	0.00392	0.0103	CcSEcCtD
Moclobemide—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00341	0.00896	CcSEcCtD
Moclobemide—Stomatitis—Teniposide—lymphatic system cancer	0.00336	0.00884	CcSEcCtD
Moclobemide—Angina pectoris—Fludarabine—lymphatic system cancer	0.00331	0.00871	CcSEcCtD
Moclobemide—Sweating—Teniposide—lymphatic system cancer	0.00331	0.00869	CcSEcCtD
Moclobemide—Appetite absent—Methotrexate—lymphatic system cancer	0.00323	0.00849	CcSEcCtD
Moclobemide—Disorientation—Bleomycin—lymphatic system cancer	0.00323	0.00847	CcSEcCtD
Moclobemide—Dysuria—Fludarabine—lymphatic system cancer	0.00318	0.00836	CcSEcCtD
Moclobemide—Urine output increased—Vincristine—lymphatic system cancer	0.00299	0.00787	CcSEcCtD
Moclobemide—Stomatitis—Fludarabine—lymphatic system cancer	0.00296	0.00777	CcSEcCtD
Moclobemide—Flushing—Teniposide—lymphatic system cancer	0.00287	0.00755	CcSEcCtD
Moclobemide—Polyuria—Vincristine—lymphatic system cancer	0.00274	0.00719	CcSEcCtD
Moclobemide—Visual impairment—Fludarabine—lymphatic system cancer	0.00262	0.00689	CcSEcCtD
Moclobemide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0026	0.00682	CcSEcCtD
Moclobemide—Agitation—Teniposide—lymphatic system cancer	0.00248	0.00651	CcSEcCtD
Moclobemide—Hypertension—Teniposide—lymphatic system cancer	0.00233	0.00612	CcSEcCtD
Moclobemide—Chest pain—Teniposide—lymphatic system cancer	0.0023	0.00603	CcSEcCtD
Moclobemide—Confusional state—Teniposide—lymphatic system cancer	0.00222	0.00583	CcSEcCtD
Moclobemide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0022	0.00578	CcSEcCtD
Moclobemide—Agitation—Fludarabine—lymphatic system cancer	0.00218	0.00572	CcSEcCtD
Moclobemide—Stomatitis—Bleomycin—lymphatic system cancer	0.00217	0.00569	CcSEcCtD
Moclobemide—Tachycardia—Teniposide—lymphatic system cancer	0.00215	0.00564	CcSEcCtD
Moclobemide—Malaise—Fludarabine—lymphatic system cancer	0.00214	0.00562	CcSEcCtD
Moclobemide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00213	0.00559	CcSEcCtD
Moclobemide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00211	0.00555	CcSEcCtD
Moclobemide—Hypotension—Teniposide—lymphatic system cancer	0.00206	0.0054	CcSEcCtD
Moclobemide—Gingivitis—Methotrexate—lymphatic system cancer	0.00205	0.00538	CcSEcCtD
Moclobemide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00204	0.00537	CcSEcCtD
Moclobemide—Myalgia—Fludarabine—lymphatic system cancer	0.00202	0.0053	CcSEcCtD
Moclobemide—Discomfort—Fludarabine—lymphatic system cancer	0.00199	0.00524	CcSEcCtD
Moclobemide—Dyspnoea—Teniposide—lymphatic system cancer	0.00196	0.00516	CcSEcCtD
Moclobemide—Confusional state—Fludarabine—lymphatic system cancer	0.00195	0.00512	CcSEcCtD
Moclobemide—Dysuria—Vincristine—lymphatic system cancer	0.00194	0.00511	CcSEcCtD
Moclobemide—Decreased appetite—Teniposide—lymphatic system cancer	0.00191	0.00503	CcSEcCtD
Moclobemide—Vomiting—Mechlorethamine—lymphatic system cancer	0.0019	0.00499	CcSEcCtD
Moclobemide—Stomatitis—Carmustine—lymphatic system cancer	0.00189	0.00497	CcSEcCtD
Moclobemide—Rash—Mechlorethamine—lymphatic system cancer	0.00188	0.00495	CcSEcCtD
Moclobemide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00188	0.00494	CcSEcCtD
Moclobemide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00187	0.00491	CcSEcCtD
Moclobemide—Flushing—Bleomycin—lymphatic system cancer	0.00185	0.00487	CcSEcCtD
Moclobemide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00181	0.00477	CcSEcCtD
Moclobemide—Stomatitis—Vincristine—lymphatic system cancer	0.00181	0.00475	CcSEcCtD
Moclobemide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.0018	0.00474	CcSEcCtD
Moclobemide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.0018	0.00473	CcSEcCtD
Moclobemide—Sweating—Vincristine—lymphatic system cancer	0.00178	0.00467	CcSEcCtD
Moclobemide—Nausea—Mechlorethamine—lymphatic system cancer	0.00177	0.00466	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00176	0.00463	CcSEcCtD
Moclobemide—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00176	0.00462	CcSEcCtD
Moclobemide—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00175	0.00461	CcSEcCtD
Moclobemide—Urticaria—Teniposide—lymphatic system cancer	0.00175	0.00459	CcSEcCtD
Moclobemide—Abdominal pain—Teniposide—lymphatic system cancer	0.00174	0.00457	CcSEcCtD
Moclobemide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00174	0.00456	CcSEcCtD
Moclobemide—Hallucination—Carmustine—lymphatic system cancer	0.00173	0.00456	CcSEcCtD
Moclobemide—Sweating—Mitoxantrone—lymphatic system cancer	0.00173	0.00455	CcSEcCtD
Moclobemide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00172	0.00453	CcSEcCtD
Moclobemide—Dyspepsia—Fludarabine—lymphatic system cancer	0.0017	0.00447	CcSEcCtD
Moclobemide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.0017	0.00446	CcSEcCtD
Moclobemide—Dysarthria—Methotrexate—lymphatic system cancer	0.0017	0.00446	CcSEcCtD
Moclobemide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00168	0.00442	CcSEcCtD
Moclobemide—Visual impairment—Carmustine—lymphatic system cancer	0.00168	0.00441	CcSEcCtD
Moclobemide—Fatigue—Fludarabine—lymphatic system cancer	0.00167	0.00438	CcSEcCtD
Moclobemide—Hallucination—Vincristine—lymphatic system cancer	0.00165	0.00435	CcSEcCtD
Moclobemide—Constipation—Fludarabine—lymphatic system cancer	0.00165	0.00435	CcSEcCtD
Moclobemide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00165	0.00433	CcSEcCtD
Moclobemide—Flushing—Carmustine—lymphatic system cancer	0.00162	0.00425	CcSEcCtD
Moclobemide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00161	0.00424	CcSEcCtD
Moclobemide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00159	0.00419	CcSEcCtD
Moclobemide—Asthenia—Teniposide—lymphatic system cancer	0.00158	0.00415	CcSEcCtD
Moclobemide—Malaise—Bleomycin—lymphatic system cancer	0.00157	0.00412	CcSEcCtD
Moclobemide—Pruritus—Teniposide—lymphatic system cancer	0.00156	0.00409	CcSEcCtD
Moclobemide—Diarrhoea—Teniposide—lymphatic system cancer	0.00151	0.00396	CcSEcCtD
Moclobemide—Chest pain—Bleomycin—lymphatic system cancer	0.00148	0.00389	CcSEcCtD
Moclobemide—Myalgia—Bleomycin—lymphatic system cancer	0.00148	0.00389	CcSEcCtD
Moclobemide—Discomfort—Bleomycin—lymphatic system cancer	0.00146	0.00384	CcSEcCtD
Moclobemide—Urine output increased—Methotrexate—lymphatic system cancer	0.00145	0.00382	CcSEcCtD
Moclobemide—Confusional state—Bleomycin—lymphatic system cancer	0.00143	0.00376	CcSEcCtD
Moclobemide—Vision blurred—Carmustine—lymphatic system cancer	0.00143	0.00376	CcSEcCtD
Moclobemide—Tremor—Carmustine—lymphatic system cancer	0.00142	0.00373	CcSEcCtD
Moclobemide—Vomiting—Teniposide—lymphatic system cancer	0.0014	0.00368	CcSEcCtD
Moclobemide—Agitation—Carmustine—lymphatic system cancer	0.00139	0.00366	CcSEcCtD
Moclobemide—Asthenia—Fludarabine—lymphatic system cancer	0.00139	0.00365	CcSEcCtD
Moclobemide—Rash—Teniposide—lymphatic system cancer	0.00139	0.00365	CcSEcCtD
Moclobemide—Dermatitis—Teniposide—lymphatic system cancer	0.00139	0.00364	CcSEcCtD
Moclobemide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00138	0.00363	CcSEcCtD
Moclobemide—Headache—Teniposide—lymphatic system cancer	0.00138	0.00362	CcSEcCtD
Moclobemide—Pruritus—Fludarabine—lymphatic system cancer	0.00137	0.0036	CcSEcCtD
Moclobemide—Agitation—Vincristine—lymphatic system cancer	0.00133	0.0035	CcSEcCtD
Moclobemide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00133	0.00349	CcSEcCtD
Moclobemide—Polyuria—Methotrexate—lymphatic system cancer	0.00133	0.00349	CcSEcCtD
Moclobemide—Hypotension—Bleomycin—lymphatic system cancer	0.00133	0.00348	CcSEcCtD
Moclobemide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00132	0.00348	CcSEcCtD
Moclobemide—Hypertension—Carmustine—lymphatic system cancer	0.00131	0.00344	CcSEcCtD
Moclobemide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00131	0.00344	CcSEcCtD
Moclobemide—Nausea—Teniposide—lymphatic system cancer	0.00131	0.00343	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00129	0.00339	CcSEcCtD
Moclobemide—Chest pain—Carmustine—lymphatic system cancer	0.00129	0.00339	CcSEcCtD
Moclobemide—Myalgia—Carmustine—lymphatic system cancer	0.00129	0.00339	CcSEcCtD
Moclobemide—Anxiety—Carmustine—lymphatic system cancer	0.00129	0.00338	CcSEcCtD
Moclobemide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00127	0.00335	CcSEcCtD
Moclobemide—Malaise—Mitoxantrone—lymphatic system cancer	0.00127	0.00334	CcSEcCtD
Moclobemide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00126	0.00332	CcSEcCtD
Moclobemide—Hypertension—Vincristine—lymphatic system cancer	0.00125	0.00328	CcSEcCtD
Moclobemide—Confusional state—Carmustine—lymphatic system cancer	0.00125	0.00328	CcSEcCtD
Moclobemide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00123	0.00324	CcSEcCtD
Moclobemide—Myalgia—Vincristine—lymphatic system cancer	0.00123	0.00324	CcSEcCtD
Moclobemide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00123	0.00323	CcSEcCtD
Moclobemide—Vomiting—Fludarabine—lymphatic system cancer	0.00123	0.00323	CcSEcCtD
Moclobemide—Rash—Fludarabine—lymphatic system cancer	0.00122	0.0032	CcSEcCtD
Moclobemide—Dermatitis—Fludarabine—lymphatic system cancer	0.00122	0.0032	CcSEcCtD
Moclobemide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00122	0.0032	CcSEcCtD
Moclobemide—Headache—Fludarabine—lymphatic system cancer	0.00121	0.00318	CcSEcCtD
Moclobemide—Tachycardia—Carmustine—lymphatic system cancer	0.00121	0.00317	CcSEcCtD
Moclobemide—Myalgia—Mitoxantrone—lymphatic system cancer	0.0012	0.00315	CcSEcCtD
Moclobemide—Chest pain—Mitoxantrone—lymphatic system cancer	0.0012	0.00315	CcSEcCtD
Moclobemide—Anxiety—Mitoxantrone—lymphatic system cancer	0.0012	0.00314	CcSEcCtD
Moclobemide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00119	0.00312	CcSEcCtD
Moclobemide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00117	0.00307	CcSEcCtD
Moclobemide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00117	0.00307	CcSEcCtD
Moclobemide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00116	0.00305	CcSEcCtD
Moclobemide—Hypotension—Carmustine—lymphatic system cancer	0.00116	0.00304	CcSEcCtD
Moclobemide—Nausea—Fludarabine—lymphatic system cancer	0.00115	0.00302	CcSEcCtD
Moclobemide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00114	0.003	CcSEcCtD
Moclobemide—Shock—Mitoxantrone—lymphatic system cancer	0.00113	0.00297	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00113	0.00296	CcSEcCtD
Moclobemide—Urticaria—Bleomycin—lymphatic system cancer	0.00113	0.00296	CcSEcCtD
Moclobemide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00112	0.00295	CcSEcCtD
Moclobemide—Insomnia—Carmustine—lymphatic system cancer	0.00112	0.00294	CcSEcCtD
Moclobemide—Irritability—Methotrexate—lymphatic system cancer	0.00111	0.00293	CcSEcCtD
Moclobemide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00111	0.00292	CcSEcCtD
Moclobemide—Paraesthesia—Carmustine—lymphatic system cancer	0.00111	0.00292	CcSEcCtD
Moclobemide—Hypotension—Vincristine—lymphatic system cancer	0.0011	0.0029	CcSEcCtD
Moclobemide—Dyspnoea—Carmustine—lymphatic system cancer	0.0011	0.0029	CcSEcCtD
Moclobemide—Somnolence—Carmustine—lymphatic system cancer	0.0011	0.00289	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00108	0.00283	CcSEcCtD
Moclobemide—Decreased appetite—Carmustine—lymphatic system cancer	0.00108	0.00283	CcSEcCtD
Moclobemide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00108	0.00283	CcSEcCtD
Moclobemide—Insomnia—Vincristine—lymphatic system cancer	0.00107	0.00281	CcSEcCtD
Moclobemide—Paraesthesia—Vincristine—lymphatic system cancer	0.00106	0.00279	CcSEcCtD
Moclobemide—Constipation—Carmustine—lymphatic system cancer	0.00106	0.00278	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00105	0.00275	CcSEcCtD
Moclobemide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00103	0.00272	CcSEcCtD
Moclobemide—Decreased appetite—Vincristine—lymphatic system cancer	0.00103	0.0027	CcSEcCtD
Moclobemide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00103	0.0027	CcSEcCtD
Moclobemide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00102	0.00269	CcSEcCtD
Moclobemide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00102	0.00268	CcSEcCtD
Moclobemide—Fatigue—Vincristine—lymphatic system cancer	0.00102	0.00268	CcSEcCtD
Moclobemide—Asthenia—Bleomycin—lymphatic system cancer	0.00102	0.00267	CcSEcCtD
Moclobemide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00101	0.00266	CcSEcCtD
Moclobemide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00101	0.00266	CcSEcCtD
Moclobemide—Constipation—Vincristine—lymphatic system cancer	0.00101	0.00266	CcSEcCtD
Moclobemide—Pruritus—Bleomycin—lymphatic system cancer	0.001	0.00264	CcSEcCtD
Moclobemide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.001	0.00263	CcSEcCtD
Moclobemide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000992	0.00261	CcSEcCtD
Moclobemide—Constipation—Mitoxantrone—lymphatic system cancer	0.000984	0.00259	CcSEcCtD
Moclobemide—Abdominal pain—Carmustine—lymphatic system cancer	0.000979	0.00257	CcSEcCtD
Moclobemide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000966	0.00254	CcSEcCtD
Moclobemide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000948	0.00249	CcSEcCtD
Moclobemide—Dysuria—Methotrexate—lymphatic system cancer	0.000943	0.00248	CcSEcCtD
Moclobemide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000941	0.00247	CcSEcCtD
Moclobemide—Abdominal pain—Vincristine—lymphatic system cancer	0.000934	0.00245	CcSEcCtD
Moclobemide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000914	0.0024	CcSEcCtD
Moclobemide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00091	0.00239	CcSEcCtD
Moclobemide—Vomiting—Bleomycin—lymphatic system cancer	0.000902	0.00237	CcSEcCtD
Moclobemide—Drowsiness—Methotrexate—lymphatic system cancer	0.000899	0.00236	CcSEcCtD
Moclobemide—Rash—Bleomycin—lymphatic system cancer	0.000894	0.00235	CcSEcCtD
Moclobemide—Dermatitis—Bleomycin—lymphatic system cancer	0.000893	0.00235	CcSEcCtD
Moclobemide—Asthenia—Carmustine—lymphatic system cancer	0.000888	0.00233	CcSEcCtD
Moclobemide—Stomatitis—Methotrexate—lymphatic system cancer	0.000876	0.0023	CcSEcCtD
Moclobemide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000874	0.0023	CcSEcCtD
Moclobemide—Sweating—Methotrexate—lymphatic system cancer	0.000862	0.00226	CcSEcCtD
Moclobemide—Asthenia—Vincristine—lymphatic system cancer	0.000848	0.00223	CcSEcCtD
Moclobemide—Diarrhoea—Carmustine—lymphatic system cancer	0.000847	0.00223	CcSEcCtD
Moclobemide—Nausea—Bleomycin—lymphatic system cancer	0.000842	0.00221	CcSEcCtD
Moclobemide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000826	0.00217	CcSEcCtD
Moclobemide—Dizziness—Carmustine—lymphatic system cancer	0.000819	0.00215	CcSEcCtD
Moclobemide—Diarrhoea—Vincristine—lymphatic system cancer	0.000809	0.00212	CcSEcCtD
Moclobemide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000787	0.00207	CcSEcCtD
Moclobemide—Vomiting—Carmustine—lymphatic system cancer	0.000787	0.00207	CcSEcCtD
Moclobemide—Dizziness—Vincristine—lymphatic system cancer	0.000781	0.00205	CcSEcCtD
Moclobemide—Rash—Carmustine—lymphatic system cancer	0.000781	0.00205	CcSEcCtD
Moclobemide—Dermatitis—Carmustine—lymphatic system cancer	0.00078	0.00205	CcSEcCtD
Moclobemide—Visual impairment—Methotrexate—lymphatic system cancer	0.000778	0.00204	CcSEcCtD
Moclobemide—Headache—Carmustine—lymphatic system cancer	0.000776	0.00204	CcSEcCtD
Moclobemide—Tinnitus—Methotrexate—lymphatic system cancer	0.000752	0.00198	CcSEcCtD
Moclobemide—Vomiting—Vincristine—lymphatic system cancer	0.000751	0.00197	CcSEcCtD
Moclobemide—Rash—Vincristine—lymphatic system cancer	0.000745	0.00196	CcSEcCtD
Moclobemide—Dermatitis—Vincristine—lymphatic system cancer	0.000744	0.00196	CcSEcCtD
Moclobemide—Headache—Vincristine—lymphatic system cancer	0.00074	0.00195	CcSEcCtD
Moclobemide—Nausea—Carmustine—lymphatic system cancer	0.000735	0.00193	CcSEcCtD
Moclobemide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000732	0.00192	CcSEcCtD
Moclobemide—Rash—Mitoxantrone—lymphatic system cancer	0.000726	0.00191	CcSEcCtD
Moclobemide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000725	0.0019	CcSEcCtD
Moclobemide—Headache—Mitoxantrone—lymphatic system cancer	0.000721	0.00189	CcSEcCtD
Moclobemide—Nausea—Vincristine—lymphatic system cancer	0.000702	0.00184	CcSEcCtD
Moclobemide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000688	0.00181	CcSEcCtD
Moclobemide—Nausea—Mitoxantrone—lymphatic system cancer	0.000684	0.0018	CcSEcCtD
Moclobemide—Vision blurred—Methotrexate—lymphatic system cancer	0.000662	0.00174	CcSEcCtD
Moclobemide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000652	0.00171	CcSEcCtD
Moclobemide—Malaise—Methotrexate—lymphatic system cancer	0.000634	0.00166	CcSEcCtD
Moclobemide—Chest pain—Methotrexate—lymphatic system cancer	0.000598	0.00157	CcSEcCtD
Moclobemide—Myalgia—Methotrexate—lymphatic system cancer	0.000598	0.00157	CcSEcCtD
Moclobemide—Discomfort—Methotrexate—lymphatic system cancer	0.000591	0.00155	CcSEcCtD
Moclobemide—Confusional state—Methotrexate—lymphatic system cancer	0.000578	0.00152	CcSEcCtD
Moclobemide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000554	0.00146	CcSEcCtD
Moclobemide—Hypotension—Methotrexate—lymphatic system cancer	0.000536	0.00141	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000522	0.00137	CcSEcCtD
Moclobemide—Insomnia—Methotrexate—lymphatic system cancer	0.000519	0.00136	CcSEcCtD
Moclobemide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000515	0.00135	CcSEcCtD
Moclobemide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000511	0.00134	CcSEcCtD
Moclobemide—Somnolence—Methotrexate—lymphatic system cancer	0.00051	0.00134	CcSEcCtD
Moclobemide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000505	0.00133	CcSEcCtD
Moclobemide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000498	0.00131	CcSEcCtD
Moclobemide—Fatigue—Methotrexate—lymphatic system cancer	0.000494	0.0013	CcSEcCtD
Moclobemide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000473	0.00124	CcSEcCtD
Moclobemide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000469	0.00123	CcSEcCtD
Moclobemide—Urticaria—Methotrexate—lymphatic system cancer	0.000456	0.0012	CcSEcCtD
Moclobemide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000453	0.00119	CcSEcCtD
Moclobemide—Asthenia—Methotrexate—lymphatic system cancer	0.000411	0.00108	CcSEcCtD
Moclobemide—Pruritus—Methotrexate—lymphatic system cancer	0.000406	0.00107	CcSEcCtD
Moclobemide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000392	0.00103	CcSEcCtD
Moclobemide—Dizziness—Methotrexate—lymphatic system cancer	0.000379	0.000996	CcSEcCtD
Moclobemide—Vomiting—Methotrexate—lymphatic system cancer	0.000365	0.000958	CcSEcCtD
Moclobemide—Rash—Methotrexate—lymphatic system cancer	0.000362	0.00095	CcSEcCtD
Moclobemide—Dermatitis—Methotrexate—lymphatic system cancer	0.000361	0.000949	CcSEcCtD
Moclobemide—Headache—Methotrexate—lymphatic system cancer	0.000359	0.000944	CcSEcCtD
Moclobemide—Nausea—Methotrexate—lymphatic system cancer	0.000341	0.000895	CcSEcCtD
